Source Paper
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Peripheral LPS Administration
Administer lipopolysaccharide peripherally to mice to activate IDO and induce inflammatory response
Note: This treatment culminates in depressive-like behavioral syndrome
View evidence from paper
“peripheral administration of lipopolysaccharide (LPS) activates IDO and culminates in a distinct depressive-like behavioral syndrome”
Forced Swim Test
Place mice in forced swim apparatus and measure duration of immobility as indicator of depressive-like behavior
Note: Immobility duration is quantified as primary outcome measure
View evidence from paper
“measured by increased duration of immobility in both the forced swim and tail suspension tests”
Tail Suspension Test
Suspend mice by tail and measure duration of immobility as indicator of depressive-like behavior
Note: Immobility duration is quantified as primary outcome measure
View evidence from paper
“measured by increased duration of immobility in both the forced swim and tail suspension tests”
IDO Blockade with Minocycline (Optional Treatment Group)
Administer minocycline to block IDO activation indirectly by attenuating LPS-induced proinflammatory cytokine expression
Note: Prevents development of depressive-like behavior when administered to LPS-treated mice
View evidence from paper
“Blockade of IDO activation either indirectly with the anti-inflammatory tetracycline derivative minocycline, that attenuates LPS-induced expression of proinflammatory cytokines”
IDO Blockade with 1-MT (Optional Treatment Group)
Administer 1-methyltryptophan to directly block IDO activation
Note: Prevents development of depressive-like behavior when administered to LPS-treated mice
View evidence from paper
“or directly with the IDO antagonist 1-methyltryptophan (1-MT), prevents development of depressive-like behavior”
L-kynurenine Administration (Optional Treatment Group)
Administer L-kynurenine to naive mice in dose-dependent manner to induce depressive-like behavior
Note: Demonstrates that kynurenine pathway metabolite alone can induce depressive-like behavior
View evidence from paper
“Administration of L-kynurenine, a metabolite of tryptophan that is generated by IDO, to naive mice dose-dependently induces depressive-like behavior”
Plasma and Brain Kynurenine/Tryptophan Ratio Measurement
Measure kynurenine/tryptophan ratio in plasma and brain samples from treated mice
Note: Both minocycline and 1-MT normalize this ratio in LPS-treated mice
View evidence from paper
“Both minocycline and 1-MT normalize the kynurenine/tryptophan ratio in the plasma and brain of LPS-treated mice”
Brain Serotonin Turnover Measurement
Measure brain serotonin turnover in treated mice
Note: Minocycline and 1-MT do not change LPS-induced increase in brain serotonin turnover
View evidence from paper
“without changing the LPS-induced increase in turnover of brain serotonin”